Informação sobre produto
- (2-{[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl}-1H-indol-1-yl)acetic acid
- 1H-Indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]-
- 2-(2-((4-(2-Chlorophenyl)thiazol-2-yl)carbamoyl)-1H-indol-1-yl)acetic acid
- 2-[2-[[4-(2-Chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid hydrate
- 2-[[N-[4-(2-Chlorophenyl)-2-thiazolyl]amino]carbonyl]-1H-indole-1-acetic acid
- 2-[[[4-(2-Chlorophenyl)-2-thiazolyl]amino]carbonyl]-1H-indole-1-acetic acid
- Lintitript
- Sr 27897B
- Sr-27897
- [2-[4-(2-Chloro-phenyl)-thiazol-2-ylcarbamoyl]-indol-1-yl]-acetic acid
- Ver mais sinónimos
SR 27897 is a novel, non-peptide, orally active agent that selectively activates the receptor for substance P. Animal studies have shown that SR 27897 has a hypoglycemic effect and can reduce food intake. The drug binds to the receptor for substance P and inhibits the release of acetylcholine from nerve terminals in the bladder, which may be due to its ability to release melatonin from pineal gland cells. It is also thought that SR 27897 may have therapeutic potential in treating cancer.
Propriedades químicas
Consulta técnica sobre: 3D-LFA38185 SR 27897
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.